Previous 10 |
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity PR Newswire ATLANTA , April 1, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company...
Inhibikase Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Virtual Conference Inhibikase Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Virtual Conference PR Newswire ATLANTA , Mar. 2, 2021 /PRNewswire/ --&...
Inhibikase Therapeutics to Present at the American Society of Experimental Neurotherapeutics (ASENT) Conference Therapeutic outcome data for oral IkT-148009 demonstrated inhibition of the Abelson Tyrosine Kinase c-Abl may lead to functional recovery PR Newswire ATL...
Inhibikase Therapeutics (IKT) announces dosing of the first patients in its Phase 1 clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson’s disease.The randomized Phase 1 study is investigating the safety, tolerability and pharmaco...
- IKT-148009 is a mechanistically defined disease-modifying therapy - Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, today ann...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The Q4 earnings season cranks up with Procter & Gamble (NYSE:PG), Netflix (NASDAQ:NFLX) and Intel (NASDAQ:INTC) some...
Four IPOs are scheduled to raise $1.8 billion in the shortened holiday week, featuring a diverse group of foreign issuers. China's leading e-cigarette brand RLX Technology plans to raise $1.0 billion at a $14.0 billion market cap. Street research is expected for Inhibikase Therape...
Inhibikase Therapeutics Announces Partnership with Clintrex Research Corporation; C. Warren Olanow, MD, to Serve as Interim Chief Medical Officer PR Newswire ATLANTA , Jan. 4, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a c...
News, Short Squeeze, Breakout and More Instantly...
Inhibikase Therapeutics Inc. Company Name:
IKT Stock Symbol:
NASDAQ Market:
Inhibikase Therapeutics Inc. Website:
BOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinso...
- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kin...
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson...